(No. DST/INSPIRE Fellowship/2012/482) and Alagappa Uni-
versity for AURF (No. Ph.D./1122/AURF FELLOWSHIP/
2015) respectively.References
- Song CM, Lim SJ, Tong JC (2009) Recent
advances in computer-aided drug design.
Brief Bioinform 10:579–591 - Clark DE, Pickett SD (2000) Computational
methods for the prediction of ’drug-likeness’.
Drug Discov Today 5:49–58 - Loving K, Alberts I, Sherman W (2010)
Computational approaches for fragment-
based andde novodesign. Curr Top Med
Chem 10:14–32 - Moon JB, Howe WJ (1991) Computer design
of bioactive molecules: a method for receptor-
based de novo ligand design. Proteins
11:314–328 - Joseph-McCarthy D (1999) Computational
approaches to structure-based ligand design.
Pharmacol Ther 84:179–191 - Aparoy P, Reddy KK, Reddanna P (2012)
Structure and ligand based drug design stra-
tegies in the development of novel 5- LOX
inhibitors. Curr Med Chem 19:3763–3778 - Po-Ssu H, Boyken SE, Baker D (2016) The
coming of age ofde novo protein design.
Nature 537:320–327 - Schneider G, Fechner U (2005) Computer-
basedde novodesign of drug-like molecules.
Nat Rev Drug Discov 4:649–663 - Hartenfeller M, Schneider G (2011) Enabling
future drug discovery byde novodesign. Wiley
Interdiscip Rev Comput Mol Sci 1:742–759 - Butina D, Segall MD, Frankcombe K (2002)
Predicting ADME propertiesin silico: meth-
ods and models. Drug Discov Today 7:
S83–S88 - Takeda S, Kaneko H, Funatsu K (2016)
Chemical-space-basedde novodesign method
to generate drug-like molecules. J Chem Inf
Model 56:1885–1893 - Jain SK, Agrawal A, Stahl M, Schneider P
(2004) De novo drug design: an overview.
Indian J Pharm Sci 66:721–728 - Hilpert K, Ackermann J, Banner DW, Gast A,
Gubernator K, Hadva ́ry P, Labler L, Mu ̈ller K,
Schmid G, Tschopp TB, Waterbeemd HVD
(1994) Design and synthesis of potent and
highly selective thrombin inhibitors. J Med
Chem 37:3889–3901 - Webber SE, Bleckman TM, Attard J, Deal JG,
Kathardekar V, Welsh KM, Webber S, Janson
CA, Matthews DA, Smith WW, Freer ST, Jor-
dan SR, Bacquet RJ, Howland EF, Booth
CLJ, Ward RW, Hermann SM, White J,
Morse CA, Hilliard JA, Bartlett CA (1993)
Design of thymidylate synthase inhibitors
using protein crystal structures: the synthesis
and biological evaluation of a novel class of
5-substituted quinazolinones. J Med Chem
36:733–746- Greer J, Erickson JW, Baldwin JJ, Varney MD
(1994) Application of the three-dimensional
structures of protein target molecules in
structure-based drug design. J Med Chem
37:1035–1054 - Baldwin JJ, Ponticello GS, Anderson PS,
Christy ME, Murcko MA, Randall WC,
Schwam H, Sugrue MF, Springer JP,
Gautheron P, Grove J, Mallorga P, Viadert
MP, McKeever BM, Navia MA (1989) Thie-
nothiopyran-2-sulfonamides: novel topically
active carbonic anhydrase inhibitors for the
treatment of glaucoma. J Med Chem
32:2510–2513 - Verlinde CL, Callens M, Van Calenbergh S,
Van Aerschot A, Herdewijn P, Hannaert V,
Michels PA, Opperdoes FR, Hol WG (1994)
Selective inhibition of trypanosomal glyceral-
dehyde-3-phosphate dehydrogenase by pro-
tein structure-based design: toward new
drugs for the treatment of sleeping sickness.
J Med Chem 37:3605–3613 - Von Itzstein M, Wu WY, Kok GB, Pegg MS,
Dyason JC, Jin B, Van Phan T, Smythe ML,
White HF, Oliver SW, Colman PM, Varghese
JN, Ryan DM, Woods JM, Bethell RC,
Hotham VJ, Cameron JM, Penn CR (1993)
Rational design of potent sialidase-based inhi-
bitors of influenza virus replication. Nature
363:418–423 - Diana GD, Treasurywala AM, Bailey TR,
Oglesby RC, Pevear DC, Dutko FJ (1990) A
model for compounds active against human
Rhinovirus-14 based on X-ray crystallography
data. J Med Chem 33:1306–1311 - Diana GD, Treasurywala A (1991) Design of
compounds active against HRV-14. Drug
News Perspect 4:517–523 - Schmidt JM, Mercure J, Tremblay GB,
Page ́M, Kalbakji A, Feher M, Dunn-Dufault-
R, Peter MG, Redden PR (2003)De novo
82 Venkatesan Suryanarayanan et al.